Real-World Effectiveness and Safety of Tofacitinib in Patients With Ulcerative Colitis: Systematic Review With Meta-Analysis
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Real-World Effectiveness and Safety of Tofacitinib in Patients With Ulcerative Colitis: Systematic Review With Meta-Analysis
Authors
Keywords
-
Journal
INFLAMMATORY BOWEL DISEASES
Volume -, Issue -, Pages -
Publisher
Oxford University Press (OUP)
Online
2021-02-16
DOI
10.1093/ibd/izab011
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Tofacitinib for rescue therapy in acute severe ulcerative colitis: a real-world experience
- (2020) Prashant Kotwani et al. Journal of Crohns & Colitis
- P512 Efficacy of tofacitinib for the treatment of moderate-to-severe ulcerative colitis: real-world data
- (2020) Y XIAO et al. Journal of Crohns & Colitis
- P648 Efficacy including rapid response and safety of tofacitinib in Japanese patients with ulcerative colitis: A preliminary investigation in a specialised IBD centre
- (2020) K Watanabe et al. Journal of Crohns & Colitis
- P662 Efficacy and safety of tofacitinib in patients with moderate-to-severe ulcerative colitis: A real-world retrospective study
- (2020) N Yoshimura et al. Journal of Crohns & Colitis
- P663 Efficacy of tofacitinib in patients with ulcerative colitis after previous ineffective biological therapies
- (2020) M Rutka et al. Journal of Crohns & Colitis
- Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry
- (2020) Vince B. C. Biemans et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Tu1895 TOFACITINIB INDUCES CLINICAL AND ENDOSCOPIC REMISSION IN BIOLOGIC REFRACTORY ULCERATIVE COLITIS PATIENTS: A REAL-WORLD BELGIUM COHORT STUDY
- (2020) Anneline Cremer et al. GASTROENTEROLOGY
- Mo1858 ENDOSCOPIC AND HISTOLOGIC OUTCOME IN TOFACITINIB TREATED REFRACTORY MODERATE-TO-SEVERE ULCERATIVE COLITIS: A PROSPECTIVE REAL-LIFE COHORT
- (2020) Bram Verstockt et al. GASTROENTEROLOGY
- Real-world Effectiveness of Tofacitinib for Moderate to Severe Ulcerative Colitis: A Multicentre UK Experience
- (2020) Sailish Honap et al. Journal of Crohns & Colitis
- Tofacitinib in Acute Severe Ulcerative Colitis—A Real-World Tertiary Center Experience
- (2020) Sailish Honap et al. INFLAMMATORY BOWEL DISEASES
- Real-World Experience with Tofacitinib in IBD at a Tertiary Center
- (2019) Roni Weisshof et al. DIGESTIVE DISEASES AND SCIENCES
- 797 – Real-World Safety of Tofacitinib in Inflammatory Bowel Diseases: A Multi-Center Study
- (2019) Parakkal Deepak et al. GASTROENTEROLOGY
- 796 – Real-World Effectiveness of Tofacitinib in Ulcerative Colitis; a Multi-Center Study
- (2019) Anish Patel et al. GASTROENTEROLOGY
- Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open
- (2019) Bruce E. Sands et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Real-world evidence of tofacitinib effectiveness and safety in patients with refractory ulcerative colitis
- (2019) Loriane Lair-Mehiri et al. DIGESTIVE AND LIVER DISEASE
- Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease
- (2018) Stefan Schreiber et al. JOURNAL OF GASTROENTEROLOGY
- Efficacy of Induction Therapy with High-intensity Tofacitinib in 4 Patients with Acute Severe Ulcerative Colitis
- (2018) Jeffrey A. Berinstein et al. Clinical Gastroenterology and Hepatology
- Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials
- (2018) William J. Sandborn et al. Clinical Gastroenterology and Hepatology
- Effectiveness of golimumab in ulcerative colitis: A review of the real world evidence
- (2018) Pablo Olivera et al. DIGESTIVE AND LIVER DISEASE
- Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis
- (2017) Carlos Taxonera et al. INFLAMMATORY BOWEL DISEASES
- Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
- (2017) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adalimumab Maintenance Treatment in Ulcerative Colitis: Outcomes by Prior Anti-TNF Use and Efficacy of Dose Escalation
- (2016) Carlos Taxonera et al. DIGESTIVE DISEASES AND SCIENCES
- Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor
- (2016) Christina Charles-Schoeman et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
- (2015) L Peyrin-Biroulet et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Update on Janus Kinase Antagonists in Inflammatory Bowel Disease
- (2014) Brigid S. Boland et al. GASTROENTEROLOGY CLINICS OF NORTH AMERICA
- Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases
- (2014) James D. Clark et al. JOURNAL OF MEDICINAL CHEMISTRY
- Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Rheumatoid Arthritis in Open-label, Longterm Extension Studies
- (2014) J. Wollenhaupt et al. JOURNAL OF RHEUMATOLOGY
- Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis
- (2013) William J. Sandborn et al. GASTROENTEROLOGY
- Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
- (2013) Brian G. Feagan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis
- (2011) William J. Sandborn et al. GASTROENTEROLOGY
- Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
- (2009) David Moher et al. PLOS MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started